# EQL Pharma > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/eqlpharma). ## Overview EQL Pharma is a pharmaceutical company focused on developing and selling generic prescription drugs and medical tests. The company operates primarily in the Nordic region and has recently expanded its market presence to include parts of Europe and the Gulf Cooperation Council (GCC) countries. EQL Pharma is known for its aggressive growth strategy, which includes launching new products and entering new markets. The company aims to achieve significant sales growth through both organic expansion and strategic acquisitions. ## Products & services • Generic prescription drugs • Medical tests for Covid and influenza • Distribution agreements in GCC countries • Hospital injection products • Unique formulations for outpatient care - **Generic Prescription Drugs** (70%) — Includes interchangeable generics for outpatient and hospital care. - **Medical Tests** (10%) — Tests for identifying Covid and influenza infections. - **Distribution Agreements** (10%) — Includes products distributed in GCC countries. - **Hospital Products** (5%) — Injection products for inpatient care. - **Unique Formulations** (5%) — Specialized products for outpatient care. - Generic prescription drugs - Medical tests for Covid and influenza - Distribution agreements in GCC countries - Hospital injection products - Unique formulations for outpatient care ## Customers EQL Pharma serves a diverse range of customer segments primarily in the healthcare sector. The company's main customers include pharmacies, hospitals, and healthcare providers who purchase generic prescription drugs. EQL Pharma also targets international markets through distribution agreements, particularly in the GCC region. The company's focus on niche markets with limited competition allows it to cater to specific healthcare needs effectively. Additionally, EQL Pharma's medical tests are used by healthcare institutions for diagnosing Covid and influenza infections. - **Pharmacies** (primary) — Purchase generic drugs for retail distribution. - **Hospitals** (secondary) — Acquire injection products for inpatient care. - **International Distributors** (emerging) — Distribute products in GCC countries. - **Healthcare Providers** (secondary) — Use unique formulations for specific treatments. - Pharmacies purchasing generic drugs for retail distribution - Hospitals acquiring injection products for inpatient care - Healthcare providers using unique formulations for specific treatments - International distributors in GCC countries for market expansion - Healthcare institutions utilizing medical tests for diagnostics ## Geography EQL Pharma operates primarily in the Nordic region, with direct sales in Sweden, Denmark, Norway, and Finland. The company has expanded its presence to include Estonia, Latvia, Lithuania, the Czech Republic, Austria, and Portugal. EQL Pharma's recent distribution agreement in the GCC countries marks a significant step in its international expansion strategy. The company sells products indirectly through partners in markets outside Europe, allowing it to reach a broader customer base. This geographic diversification helps mitigate risks associated with market-specific economic fluctuations. - Direct operations in Sweden, Denmark, Norway, and Finland - Expanded presence in Estonia, Latvia, Lithuania, Czech Republic, Austria, and Portugal - Distribution agreement in GCC countries for market expansion - Indirect sales through partners in non-European markets - Geographic diversification reduces market-specific risks ## Strategy EQL Pharma's strategic priorities focus on aggressive growth through product launches and market expansion. The company aims to achieve a 30% annual sales growth rate by expanding its product pipeline and entering new geographic markets. Strategic acquisitions play a crucial role in this growth strategy, as evidenced by the recent Medilink acquisition. EQL Pharma also prioritizes maintaining a healthy EBITDA margin of over 25% while reducing net leverage to below 2.5x. The company's focus on niche markets with limited competition supports its long-term growth objectives. - **Product Launches** (short-term) — To drive sales growth and market presence. - **Market Expansion** (medium-term) — To increase geographic reach and customer base. - **Strategic Acquisitions** (medium-term) — To enhance product offerings and competitive position. - **Margin Stability** (long-term) — To ensure financial health and investor confidence. - Aggressive growth through product launches and market expansion - Targeting 30% annual sales growth rate - Strategic acquisitions to enhance product portfolio - Maintaining EBITDA margin over 25% - Reducing net leverage to below 2.5x ## Risks EQL Pharma faces several business and financial risks, including delays in product launches and increased competition, which could impact sales and profitability. The company's aggressive growth strategy may require additional capital, posing financial risks if market conditions change. External factors such as inflation, currency fluctuations, and geopolitical risks can also affect operations. Transport disruptions, as experienced in the Red Sea, can impact supply chains and margins. Additionally, the company's reliance on strategic acquisitions introduces risks related to integration and realization of expected synergies. - **Product Launch Delays** [high] — Can lead to deterioration in earnings. - **Increased Competition** [high] — Could lead to slower sales and weaker profitability. - **Capital Requirements** [medium] — Aggressive growth strategy may need additional funding. - **Transport Disruptions** [medium] — Affects supply chains and gross margins. - Delays in product launches affecting earnings - Increased competition impacting sales and profitability - Need for additional capital in changing market conditions - External factors like inflation and currency fluctuations - Transport disruptions affecting supply chains and margins - Risks associated with strategic acquisitions ## Accounting EQL Pharma's financial statements are prepared in accordance with IFRS, with specific attention to fair value calculations for financial assets and liabilities. The company's accounting policies include the recognition of acquired products based on acquisition values and estimated useful lives. Revenue recognition and margin stability are critical areas, especially given the company's aggressive growth and acquisition strategy. The use of variable interest rate loans requires careful management of interest rate risks. Additionally, the company's focus on strategic acquisitions necessitates accurate fair value assessments and integration accounting. - **Revenue Recognition** — high - **Fair Value Calculations** — medium - **Acquisition Accounting** — high - IFRS-based financial statement preparation - Fair value calculations for financial assets and liabilities - Revenue recognition critical for growth strategy - Variable interest rate loans require risk management - Acquisition accounting for integration and fair value --- *Last updated: 2026-08-11T04:04:52.446876+00:00*